Ashurst advises BioMedion on strategic investment of Main Capital Partners

Ashurst advised BioMedion GmbH, a global life and health sciences regulatory compliance software provider, in connection with a strategic investment of Main Capital Partners.

Berlin-based BioMedion was founded in 2000 and is active in the field of regulated industries. The company provides state-of-the-art regulatory compliance software solutions for the life science industry. It achieved a clear double-digit revenue growth rate over 2021. The strategic partnership with Main Capital Partners marks the next milestone in BioMedion’s continued high-growth trajectory. With the support of Main Capital Partners, the company aims to become a leading global player in the market.

Established in 2003, Main Capital Partners with offices in The Hague, Düsseldorf and Stockholm is Europe’s leading investor in the software industry with an exclusive focus on enterprise software companies in the Benelux, DACH and Nordics regions.

The Ashurst team was led by partner Dr Gerrit Clasen and counsel Martina Rothe. They were assisted by associate Quynh Anh Le (all Corporate/M&A). Advice on tax law aspects was provided by partner Dr Anders Kraft and senior associate Dr Susanne Knoch.